BRÈVE

sur Protenus, Inc.

Protenus Secures Two Innovative Patents for Enhancing Healthcare Compliance

BALTIMORE, MD, April 2, 2024 – Protenus, a leader in healthcare compliance analytics, has been awarded two U.S. Patents, Nos. 11,735,297, and 11,862,308, titled "Methods and Systems for Analyzing Accessing of Medical Data". These patents mark the company’s fifth and sixth in the domain of patient privacy monitoring, extending its technology aimed at safeguarding patient information within hospitals and health systems. Through these technological advancements, Protenus aims to bolster hospital efficiencies and proactively mitigate risks.

The awarded patents cover a range of techniques, including the analysis of access events by employee groups to identify breaches and the detection of inconsistencies in access patterns that may indicate unauthorized data breaches. In light of over 171 million patient records breached in 2023, Protenus CEO Nick Culbertson underscores the critical need for robust technology solutions to protect sensitive patient data from insider threats effectively.

Protenus’ expanding patent portfolio, now exceeding a dozen U.S. patents, encapsulates key facets of patient privacy monitoring and drug diversion surveillance technologies. These achievements underscore the company’s commitment to innovation in healthcare compliance, offering sophisticated solutions that aid in detecting and preventing inappropriate access to patient records. Inquiries regarding the Protenus patent portfolio can be directed to General Counsel Amy Much.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Protenus, Inc.